UroGen (URGN) CMO Mark Schoenberg Sells 60,677 Shares

What Happened

• Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), sold 60,677 shares in open-market transactions on August 20, 2026. The filing reports a weighted-average sale price of $47.05, for total reported proceeds of $2,854,853.
• This was a sale (transaction code S). Sales by insiders are common and are not, by themselves, proof of a change in confidence in the company.

Key Details

• Transaction date: 2026-08-20 (reported on Form 4 filed 2026-08-24).
• Price: weighted average $47.05; individual sale prices ranged $46.30 to $49.70 per share (see footnote).
• Total proceeds: $2,854,853.
• Shares owned after transaction: not specified in this filing.
• Notable footnote: the reported price is a weighted average covering multiple transactions; the reporting person will provide a per-price breakdown on request.
• Timeliness: The Form 4 was filed four days after the transaction date and therefore appears to have been filed later than the standard two-business-day requirement.

Context

• This was an open-market sale, not an option exercise, grant, or gift. Open-market sales can be for many reasons (diversification, liquidity, taxes) and do not necessarily indicate insider views on company prospects.